Celldex Therapeutics Stock (NASDAQ: CLDX) stock price, news, charts, stock research, profile.
Day Range- - - | 52 Wk Range19.850 - 48.400 | Open / Close- / - | Float / Outstanding40.000M / 47.100M |
Vol / Avg.0 / 494.866K | Mkt Cap2.162B | P/E- | 50d Avg. Price42.740 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float40.000M | EPS-2.260 |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-05-04 | ||||||
REV |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-02-27 | ||||||
REV |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Celldex Therapeutics (NASDAQ: CLDX) through any online brokerage.
Other companies in Celldex Therapeutics’s space includes: Immunovant (NASDAQ:IMVT), Syndax Pharmaceuticals (NASDAQ:SNDX), Prothena Corp (NASDAQ:PRTA), Sage Therapeutics (NASDAQ:SAGE) and FibroGen (NASDAQ:FGEN).
The latest price target for Celldex Therapeutics (NASDAQ: CLDX) was reported by Guggenheim on Friday, November 11, 2022. The analyst firm set a price target for 63.00 expecting CLDX to rise to within 12 months (a possible 37.25% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Celldex Therapeutics (NASDAQ: CLDX) is $45.9 last updated February 7, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Celldex Therapeutics.
Celldex Therapeutics’s Q1 earnings are confirmed for Thursday, May 4, 2023.
There is no upcoming split for Celldex Therapeutics.
Celldex Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Celldex Therapeutics Stock (NASDAQ: CLDX) stock price, news, charts, stock research, profile.
Day Range- - - | 52 Wk Range19.850 - 48.400 | Open / Close- / - | Float / Outstanding40.000M / 47.100M |
Vol / Avg.0 / 494.866K | Mkt Cap2.162B | P/E- | 50d Avg. Price42.740 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float40.000M | EPS-2.260 |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-05-04 | ||||||
REV |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-02-27 | ||||||
REV |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Celldex Therapeutics (NASDAQ: CLDX) through any online brokerage.
Other companies in Celldex Therapeutics’s space includes: Immunovant (NASDAQ:IMVT), Syndax Pharmaceuticals (NASDAQ:SNDX), Prothena Corp (NASDAQ:PRTA), Sage Therapeutics (NASDAQ:SAGE) and FibroGen (NASDAQ:FGEN).
The latest price target for Celldex Therapeutics (NASDAQ: CLDX) was reported by Guggenheim on Friday, November 11, 2022. The analyst firm set a price target for 63.00 expecting CLDX to rise to within 12 months (a possible 37.25% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Celldex Therapeutics (NASDAQ: CLDX) is $45.9 last updated February 7, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Celldex Therapeutics.
Celldex Therapeutics’s Q1 earnings are confirmed for Thursday, May 4, 2023.
There is no upcoming split for Celldex Therapeutics.
Celldex Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Celldex Therapeutics Stock (NASDAQ: CLDX) stock price, news, charts, stock research, profile.
Day Range- - - | 52 Wk Range19.850 - 48.400 | Open / Close- / - | Float / Outstanding40.000M / 47.100M |
Vol / Avg.0 / 494.866K | Mkt Cap2.162B | P/E- | 50d Avg. Price42.740 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float40.000M | EPS-2.260 |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-05-04 | ||||||
REV |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-02-27 | ||||||
REV |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Celldex Therapeutics (NASDAQ: CLDX) through any online brokerage.
Other companies in Celldex Therapeutics’s space includes: Immunovant (NASDAQ:IMVT), Syndax Pharmaceuticals (NASDAQ:SNDX), Prothena Corp (NASDAQ:PRTA), Sage Therapeutics (NASDAQ:SAGE) and FibroGen (NASDAQ:FGEN).
The latest price target for Celldex Therapeutics (NASDAQ: CLDX) was reported by Guggenheim on Friday, November 11, 2022. The analyst firm set a price target for 63.00 expecting CLDX to rise to within 12 months (a possible 37.25% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Celldex Therapeutics (NASDAQ: CLDX) is $45.9 last updated February 7, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Celldex Therapeutics.
Celldex Therapeutics’s Q1 earnings are confirmed for Thursday, May 4, 2023.
There is no upcoming split for Celldex Therapeutics.
Celldex Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Celldex Therapeutics Stock (NASDAQ: CLDX) stock price, news, charts, stock research, profile.
Day Range- - - | 52 Wk Range19.850 - 48.400 | Open / Close- / - | Float / Outstanding40.000M / 47.100M |
Vol / Avg.0 / 494.866K | Mkt Cap2.162B | P/E- | 50d Avg. Price42.740 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float40.000M | EPS-2.260 |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-05-04 | ||||||
REV |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-02-27 | ||||||
REV |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Celldex Therapeutics (NASDAQ: CLDX) through any online brokerage.
Other companies in Celldex Therapeutics’s space includes: Immunovant (NASDAQ:IMVT), Syndax Pharmaceuticals (NASDAQ:SNDX), Prothena Corp (NASDAQ:PRTA), Sage Therapeutics (NASDAQ:SAGE) and FibroGen (NASDAQ:FGEN).
The latest price target for Celldex Therapeutics (NASDAQ: CLDX) was reported by Guggenheim on Friday, November 11, 2022. The analyst firm set a price target for 63.00 expecting CLDX to rise to within 12 months (a possible 37.25% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Celldex Therapeutics (NASDAQ: CLDX) is $45.9 last updated February 7, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Celldex Therapeutics.
Celldex Therapeutics’s Q1 earnings are confirmed for Thursday, May 4, 2023.
There is no upcoming split for Celldex Therapeutics.
Celldex Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Celldex Therapeutics Stock (NASDAQ: CLDX) stock price, news, charts, stock research, profile.
Day Range- - - | 52 Wk Range19.850 - 48.400 | Open / Close- / - | Float / Outstanding40.000M / 47.100M |
Vol / Avg.0 / 494.866K | Mkt Cap2.162B | P/E- | 50d Avg. Price42.740 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float40.000M | EPS-2.260 |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-05-04 | ||||||
REV |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-02-27 | ||||||
REV |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Celldex Therapeutics (NASDAQ: CLDX) through any online brokerage.
Other companies in Celldex Therapeutics’s space includes: Immunovant (NASDAQ:IMVT), Syndax Pharmaceuticals (NASDAQ:SNDX), Prothena Corp (NASDAQ:PRTA), Sage Therapeutics (NASDAQ:SAGE) and FibroGen (NASDAQ:FGEN).
The latest price target for Celldex Therapeutics (NASDAQ: CLDX) was reported by Guggenheim on Friday, November 11, 2022. The analyst firm set a price target for 63.00 expecting CLDX to rise to within 12 months (a possible 37.25% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Celldex Therapeutics (NASDAQ: CLDX) is $45.9 last updated February 7, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Celldex Therapeutics.
Celldex Therapeutics’s Q1 earnings are confirmed for Thursday, May 4, 2023.
There is no upcoming split for Celldex Therapeutics.
Celldex Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Celldex Therapeutics Stock (NASDAQ: CLDX) stock price, news, charts, stock research, profile.
Day Range- - - | 52 Wk Range19.850 - 48.400 | Open / Close- / - | Float / Outstanding40.000M / 47.100M |
Vol / Avg.0 / 494.866K | Mkt Cap2.162B | P/E- | 50d Avg. Price42.740 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float40.000M | EPS-2.260 |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-05-04 | ||||||
REV |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-02-27 | ||||||
REV |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Celldex Therapeutics (NASDAQ: CLDX) through any online brokerage.
Other companies in Celldex Therapeutics’s space includes: Immunovant (NASDAQ:IMVT), Syndax Pharmaceuticals (NASDAQ:SNDX), Prothena Corp (NASDAQ:PRTA), Sage Therapeutics (NASDAQ:SAGE) and FibroGen (NASDAQ:FGEN).
The latest price target for Celldex Therapeutics (NASDAQ: CLDX) was reported by Guggenheim on Friday, November 11, 2022. The analyst firm set a price target for 63.00 expecting CLDX to rise to within 12 months (a possible 37.25% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Celldex Therapeutics (NASDAQ: CLDX) is $45.9 last updated February 7, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Celldex Therapeutics.
Celldex Therapeutics’s Q1 earnings are confirmed for Thursday, May 4, 2023.
There is no upcoming split for Celldex Therapeutics.
Celldex Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Celldex Therapeutics Stock (NASDAQ: CLDX) stock price, news, charts, stock research, profile.
Day Range- - - | 52 Wk Range19.850 - 48.400 | Open / Close- / - | Float / Outstanding40.000M / 47.100M |
Vol / Avg.0 / 494.866K | Mkt Cap2.162B | P/E- | 50d Avg. Price42.740 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float40.000M | EPS-2.260 |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-05-04 | ||||||
REV |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-02-27 | ||||||
REV |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Celldex Therapeutics (NASDAQ: CLDX) through any online brokerage.
Other companies in Celldex Therapeutics’s space includes: Immunovant (NASDAQ:IMVT), Syndax Pharmaceuticals (NASDAQ:SNDX), Prothena Corp (NASDAQ:PRTA), Sage Therapeutics (NASDAQ:SAGE) and FibroGen (NASDAQ:FGEN).
The latest price target for Celldex Therapeutics (NASDAQ: CLDX) was reported by Guggenheim on Friday, November 11, 2022. The analyst firm set a price target for 63.00 expecting CLDX to rise to within 12 months (a possible 37.25% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Celldex Therapeutics (NASDAQ: CLDX) is $45.9 last updated February 7, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Celldex Therapeutics.
Celldex Therapeutics’s Q1 earnings are confirmed for Thursday, May 4, 2023.
There is no upcoming split for Celldex Therapeutics.
Celldex Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Celldex Therapeutics Stock (NASDAQ: CLDX) stock price, news, charts, stock research, profile.
Day Range- - - | 52 Wk Range19.850 - 48.400 | Open / Close- / - | Float / Outstanding40.000M / 47.100M |
Vol / Avg.0 / 494.866K | Mkt Cap2.162B | P/E- | 50d Avg. Price42.740 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float40.000M | EPS-2.260 |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-05-04 | ||||||
REV |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-02-27 | ||||||
REV |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Celldex Therapeutics (NASDAQ: CLDX) through any online brokerage.
Other companies in Celldex Therapeutics’s space includes: Immunovant (NASDAQ:IMVT), Syndax Pharmaceuticals (NASDAQ:SNDX), Prothena Corp (NASDAQ:PRTA), Sage Therapeutics (NASDAQ:SAGE) and FibroGen (NASDAQ:FGEN).
The latest price target for Celldex Therapeutics (NASDAQ: CLDX) was reported by Guggenheim on Friday, November 11, 2022. The analyst firm set a price target for 63.00 expecting CLDX to rise to within 12 months (a possible 37.25% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Celldex Therapeutics (NASDAQ: CLDX) is $45.9 last updated February 7, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Celldex Therapeutics.
Celldex Therapeutics’s Q1 earnings are confirmed for Thursday, May 4, 2023.
There is no upcoming split for Celldex Therapeutics.
Celldex Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Celldex Therapeutics Stock (NASDAQ: CLDX) stock price, news, charts, stock research, profile.
Day Range- - - | 52 Wk Range19.850 - 48.400 | Open / Close- / - | Float / Outstanding40.000M / 47.100M |
Vol / Avg.0 / 494.866K | Mkt Cap2.162B | P/E- | 50d Avg. Price42.740 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float40.000M | EPS-2.260 |
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-05-04 | ||||||
REV |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-02-27 | ||||||
REV |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Celldex Therapeutics (NASDAQ: CLDX) through any online brokerage.
Other companies in Celldex Therapeutics’s space includes: Immunovant (NASDAQ:IMVT), Syndax Pharmaceuticals (NASDAQ:SNDX), Prothena Corp (NASDAQ:PRTA), Sage Therapeutics (NASDAQ:SAGE) and FibroGen (NASDAQ:FGEN).
The latest price target for Celldex Therapeutics (NASDAQ: CLDX) was reported by Guggenheim on Friday, November 11, 2022. The analyst firm set a price target for 63.00 expecting CLDX to rise to within 12 months (a possible 37.25% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Celldex Therapeutics (NASDAQ: CLDX) is $45.9 last updated February 7, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Celldex Therapeutics.
Celldex Therapeutics’s Q1 earnings are confirmed for Thursday, May 4, 2023.
There is no upcoming split for Celldex Therapeutics.
Celldex Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.